Figure 7.

Regorafenib inhibits EMT by down‐regulating Snail in HCC cells. (A) Serum‐starved SMMC‐7721 cells pre‐incubated with regorafenib (0.25 μm or 0.5 μm) for 6 h were treated with HGF (10 ng·mL⁻¹) for 24 h, and cell migration was determined by a wound healing assay. (B) Serum‐starved HepG2 cells pre‐incubated with regorafenib (0.25 μm or 0.5 μm) for 6 h were treated with HGF (10 ng·mL⁻¹) for 24 h, and cell migration was determined by a wound healing assay. (C) Serum‐starved SMMC‐7721 and HepG2 cells pre‐incubated with regorafenib (0.25 μm or 0.5 μm) for 6 h were treated with HGF (10 ng·mL⁻¹) for 24 h, and cell invasion was determined by a transwell assay. (D) Serum‐starved SMMC‐7721 and HepG2 cells pre‐incubated with regorafenib (0.25 μm or 0.5 μm) for 6 h were treated with HGF (10 ng·mL⁻¹) for 1 h, and Snail was detected 3 h after treatment, whereas E‐cadherin was detected 48 h after treatment, by western blotting. The density of each band was normalized to GAPDH (*P < 0.05). Data are expressed as the mean ± SD from three individual experiments. Differences between groups were determined using Student's t‐test and two‐way ANOVA with Bonferroni correction.